"{\"eval_set_result_id\":\"capricorn_adk_agent_quickstart_eval_1754695875.339651\",\"eval_set_result_name\":\"capricorn_adk_agent_quickstart_eval_1754695875.339651\",\"eval_set_id\":\"quickstart_eval\",\"eval_case_results\":[{\"eval_set_file\":\"quickstart_eval\",\"eval_set_id\":\"quickstart_eval\",\"eval_id\":\"simple\",\"final_eval_status\":1,\"eval_metric_results\":null,\"overall_eval_metric_results\":[{\"metric_name\":\"tool_trajectory_avg_score\",\"threshold\":0.2,\"judge_model_options\":null,\"score\":1.0,\"eval_status\":1},{\"metric_name\":\"response_match_score\",\"threshold\":0.3,\"judge_model_options\":null,\"score\":0.6587677725118483,\"eval_status\":1}],\"eval_metric_result_per_invocation\":[{\"actual_invocation\":{\"invocation_id\":\"e-05464017-10cc-4d26-8ec4-05e4cb204813\",\"user_content\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":null,\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"45-year-old female with invasive\\nductal carcinoma, ER+/PR+/HER2-,\\nBRCA1 mutation, T2N1M0\"}],\"role\":\"user\"},\"final_response\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":\"CsopAVSoXO67RVak5Uj_3wb6GZ0DxdgNyWxkrFjLsb9aZMZBdx-08piqz77KtmCyASyHFFp1Smmsh7_3l6zBG-19lMutdKZUCcdQySuP8MGoa1DfbSYdB-DZs2AndP0g_IVGcNjnjJfEmBRFyedxtPfH2YkfIp4yZax_yHscuVXgtdZ-nunONoMrQX-0imheMj4xV_9OT5Mr7AnEnKY2gEMCSFBCLJSn_5m0VYo4rVZNccw8y1m1MCVYfkBGesRGFYoVvoMsh4gRd7nDTuIXHAJP3bG6tCv2-C6Bw6lvV9P7noTzoZ0lh-v9ZlxYZCZafBl6NpR6kGebkg3-3IXdZBIBB_iMmb7nkFKg1moIejrf25ckLOoVZuW7oZZ3Q8RhlRdv9b9mEa-6blONSjdmQcCY20Kpa3M6PyeEjI7rKtmBCo9p-Lz2WmSoOF5glfT7c30CA5lHt1Z7WaVvkR0tmgPmkyovC4TYWLh_aYBmSc-3JJa-qJ2D65U3yuQP3epwHjX_ystfpQQCJThwuJ8bnRaSyIWDw43zRY2xUZDYWID5P0A4aMJTyygsQ8qIaSFIOfBCvR6BSdra2vin7jWw2kDKhysh_fiTKXIN1oCTmWtskXcIZuJB_5irGw2jTfeqvE1gyDAwExnQ8TxsFv0MeFpKGCyQoiBFQLKdLU3NAqgeFSGy4PpurG5s4Ca1jXp1PGrdn4gFAYgv7nnWlbRpMgGT7RbBRfBloQTyHI0n-m8MCRK3y_RclFN5eX8NE2FAtUbmmwimEs0T3UMoVJ3gATDu4-lutgZ_7mJupzyt3UYZl7cQ2KQjI72y-ZXWc47RcSeKjb2DIXF9-c1RO3WZ4b5L0QswHI3QUYwfrWu3WBwihHICqWIXiApjXZgbL211h8eis-JFYs-SGuNkQF1xdIbmKh06dEFd9pc02syxe29Tap7z9zcExWhMKdpFAR9hadcV_rXVT4p8BED5NsZiAsMjbACAUqfoIUC17UDLNWaOA-ObYhfpCguaHOPFC8VxWb0F7YcPTycfF7K4VgOk3UpvpVsf4mTpCPrMbN4UIC8zTOzaOKsWbuXkZw3tDmVvCmq16TVMbY-G9q24Z3ysEktnRNrd24JumzGO-hYutBk2nCZHjpP-Qw4fC4gJ0lCXsRKMPwLfr89XkERLRbFrt09Hb6Dx_XIHNhtLQQ_OI_rnO5ICgiRzFpIGG2AMLibXVh4Aerq5-wQlVmYPfKocXJBp37vzBNrN0sQ-ykeOGCBddOd35_IEbXlEYTmiSfSsFWclorXeqTE-rz3z-MKJ46CX0C8qG2jWOB75F27feFLop1apHwAf5kJQc-FNdYLLaciu3Fjb21ME4751Ir-B_NH2eI8mTQkzobXmff13imVRs5u1dJzYr-g7h0ImCznOufnbvxHcIHFlc_Q9lSwZXmTTT9tHrWBZASuEqsvhvakEBd9GrbLoPpcgcEOh6BjCFDuNVpy4WKSX-1kcVUNPRpXmhTQv0KYwy1lVGRGi-fyorAInmALwXnJgb-hWtbpIMRvB33hebOyKhRHojC1-POcSTZlvNUBUkhGl6XNGFb3Ep0DaOJFZ-Dw7pHhGgf2p6YE14L_-u0zqYADLI4d9pciwWSydy0Lv0HUeqWBrskXlLMuJPW50wtSkDJzqQgveaE2_fl6DiywS80N7GFRvl5rUcN1ECvLf0UgmKtd0VECJJMx82S504NpQEBbDwOXGy5UmYxN1ZB1xwnDWU3oiAU8-1ftdIe-32QLXN2mNBoS-UCKVdNtjm6CHafFXEspp0W2CUEY0Jdl-QTPQ8UgvGgtKSXjU5pEjt7odim8GFgNSXLFvPe5rgEyNkuvUzdY9SqihJyGR1pDnPptfB8W6EV6KYKZcqZkZGCGQ0_UfIrAvwll8Hbc6uC2zQ-thMQ1hgKIO_-hzxs7IHo1Uj_S2h0ii49XoIizAV26YxAVBpr812ZfBGfuWS1APkM-WgorDlDA8du8DOz8eJl0F8H12iWN_OCiZ3spnmUbcDYN90NdfwCuWNa2wh_IdfUB-JS7x1s08bUq_sNDmkV40xvApiURI4G3ITiSRz--A9cMfYkHOutkJV2WFj2tUOTZsFY6Eeh7kr5UgemHm_Cr2pU-WWa7CFOYLx902DBC-NgPAUSIRj1S2O0phK7vyrht-pTEnYW21uar9id_U00URbIcOE5kK4hOb-sy3RIPa6Ry5I3VCJ_is_lgbd543Wd2OEgpbLfGoGjPacXFFJUVJ-vCwTQEHlkN8uix1vzF8T-QMFsn7JKO5chV25dKsjKlSVfzAI6gRlh6pxEnNMP3dFVF2xI81wxG-b1INrXkt0zCuzAV2S7QSnQe5XKD3EOiWOiNkaT_9MXb8dq9bzkdHsZam0bElZ4zeCWaZX5EXt8rk_Cs6zYRNIlKFNWDSallg1Gqv98EhkZFFlGioA7aobEkBo9E8jhbiS4BtPo4EOVsZT1SI3RjG5Zv41XFdWKh23Rjg-JCFC5ViKi-pdPdNTGKKo5uHmNT97Sp8iZsYJicEFz9wyR7wDUFYJfy8Se2uJrNqvR8VbsPQk4vCULAJrhOnDyFplfjpiyvgv4cGa1JYl8Id-APwhwrL2cqD_Zbu8FrGGV_UTc498-D-Gep9dlJbUc7_St2Bvc_lOSeAoan3KSOTnSMqHmKdTo8871EwXVvtdcF4nBghtFnpr4rWobtQW8d1hH6WxTeFF6ULgwilGT87luIJqciT1A5ixZKEoH7AgM7K5jyKeKqzmdBVhyXZPB0ee-0PdiK_S0-ODV9icymBIVYQzPm82dEvwAaY_pYoGaliu2c6_G07yHaz9c7jInq2ML_cTQTnzwiZNwWqC2mWLqHVYlhZPOQcf6rA2g-4dCgIf8Q4hGspswp7HdfvH0YZz03O2CMMQ_FqkObYXfQt68AUxFBhXqtPuKfIWX0DrHiZ4vUpgLCzY9U7KctSnoQGe_P6hW0k-TGYX5t6_SWu1QLZ-K4AZdjO24Ufz3IOoQwPzxzMPRRfl4sfYDwfn5h77sX4QcVRnEp3F9NVnWxZRJzF1ysAKhBU5L9aZ3XXa0TxumfgB4RD6WzI-n3cEdUQ5k9uOdMwl4mNU2l7Sb45TVQJlL-Vz7uwDHIWP47q5vZzX71i6EFOnBfr7HWytpkTb9-YQIi3QffuP53F7zXKQz0_xhkeVLAgeF14qpUIvAGyHgri8EHDaLziNu-L-hWnD8xN823ZRDSkY6-9L9rJzE2LgIWM5dEnJ5ddp6iCXpqn5PneW7-vtf97AKtbu6dswJ933zcHWHfF-g9IO_PRRn1PMwJ1J5JkPXKQgVTQff3ZXvLbXpFGEmlt17ZJBI1DNEOb2MGKbISou0V-8rIbg85porb6z39q-WAESjVlekVT4BDLEHoJjGF23s4VLC8nQvecX4PsZOHaDXOdaPxDeHrmku93nFFSsJFEGQ8e7mUUKQ0xgY0tY77C1FGbG1lDtL2pob0Ncr6qYHtm6qGjxtpXAEmThsMvRCAYfWJE8uDQD3eGUgWQ7xWVSuWgEbQCPoB_yu9dW8gp39zuLGckJoi2eCrLLCPvZRszQJ9yAZvfZYnD31_aYAONWb0BM0ycvkxZvlrt-hv43GtYE2gCB-VWef0vnkC62ogWMrVjcdVgp1s5bkKs-1ousqmEsEnI_6nRanvuEoWjOAI43lal4ZLIseRS6ir4LqBeP3Q5qDK8FT4RrtlDLhii76bZK7bzlUCgmcv2iAginL8gxjyXSeGrhsfFGxVU11iAPJjYBmNVYjIWHb75QcnzZPOm_Bkzcdx9OkdSIElIK8sZTK1hQk0sK5006aegOPCc8OuOFPDt-aJ5T64JEPcSLh1iavf_TGDsFjAi4K8v5oWweOBs7Dt4TxJfeFGioXKaCmYWFnG417i9uw8tKqcIn0pGc4w1BxX55qJwbczpY7EaKMH1vertZEcJLe2c_ZctGoHQY1UvObjFfu-tLgbP9nyLBNFYGc1soOZNryGf8YhwDUi3hJxSs01FX-y0ie_uXe1Fb3TS37Cr8B93QRbAo2q9yGDxnQkJjSRKiDV4k3nNxbqfN2_BERS0UOyVVI_wYCDZc7KZxpOLJ-0sLi2MR37OqlsSntHoONWRwIchb-pNEwpAqs3VOGJNBquIGkXM9D42D_WkNrCWiZCEOWPfuDK_aRhdVRIkeWaj7CREuiaySSPgS29E0JalVK3D3mCHUPA8pFfwNfpPuGm_y2GuVX3EqmjiUn5LWE867L539OsQK6Y8_vTBIUsqeXC2MFcgYjcNlkNmxpP6Vaw0PHQVU04XGewnNAPnqczOm6His5ZlkyWfrH3C9zEw6IG3I2kmo7A-2PPPPk4rY_PZQE427z5DY5xZb5U17XfwIEeJ3cX60neBS_TCVVdSdi8fnXPLu-HCuNZCDkUJq2hXj6BhMuC0hm8Dd8IP4WzEy0KzqAeQT9LICeqdivzRs8YVCLNnix02-V_qhGQ7_RLngBv1A9QzgIj61ceojBOTVHNGJxuvafRWRAT0e_sEgfX1noBGqgKNEyJvxzd0IbWpxkZz6A9I9j-VtdDHVnII__dRL_Oidb15Ht0PIXnenCKY6AEkiEP3W_zffjARSoO1qGAWOe0Q9qIvB9unJCnB6MO4K8lytT5dCNqyZw2G4MNr-wKE5-o47_z364PGdMCjzCB_crE5JDe8yTUwyZJs9J8UewS3FEKKbGLXo0n5cd3c8Kt9R0j-ecY5tRcG9FvyKqn2sIfI-s_p9Z7h_r9Ua8E3awomsaTXCsVs88eSWkcTWRrBHaK7Iuug5Hjl3oFF9OyiOHDr1LNt3OtJXOzjy-SCQyWrncRlWzovR9RKzzgg5fr6sv61s321WTEZLIvl_6pUdOGMQz5zMw9_OCLVUiXmjkAZOTjGZqbVoK3Ej6LYHNL4TW1XtnWe9_XNZ_kIQDM_fDzqzFRGxiMyK2F6oWnjg8R-Vj985FY_kWwEAn1EHYsgErVSEx4pfCeT5i0h6AK-_oQmYplTBh7xdN5w0CY1sM_N_Xax1bYg0qEYq9KgkY2PK2ivsw82XubJMRx9UVx8Myc4QksptMp4QSu9x8FNqjDZykpemje0xghDAB6Ktm8BwqNyUveC1KJNMqsH77Z3fP1WIWgQI2T5p0q7hRbr0ARu-RLlW4u38PXi5Hb4_uSaLZCKIFB7b0PxI8kbrPAEXz6QqwQooIbiEbtaRDoaoMve9skdiU7lXhgxZfkWAlI4wd90sjcyg5HaHuTuIVo04nqCCg6QDOh-q6-nNiRu_DXZ-FL7VCcsFTGoDh5Is3FUts_AcXffo4ueNK8yGmGI2jx6mH4JImF0lnZtPxSsGIDnRgo5eHNlKMJ2fBkpMozMml6v0OVPaoLalI0oLSAj6tjWalb5Wq0odVFLCoJI7NMuyZhZeWkcQ2MLwZ0n6x0QMr_HPT0LeSXyorluiH8Z_usCIv20S56V5axwexjec30THzLQ4UGK_9K0codD4jbMtAYLSQab3WVnco12PaN3mtFFa5P4fVNhymcT2r2gBFfz5WmtGmpCpFcn1TqgJ_WmJrdp5r_XLRwuy0vR1TOGES5eayVtq1LDTf1jFRkUIA-8qc5aaRiA7vgziTcY_O3p4XeznnW3nGZXDYEYl1a00maG10vkXS5K8EqXn8dcrc9bsN7OHc6wBFwjf8SntmCcmwAoCAExtzWvIkfUzvOt6GmCHRk5n8L64v880G8N4AgyXjJrwFmJTed8aPJiYi8uXaWaYiJTMB-7hi3Z4NLnZijxdlnX_QKv0VHovn344qC1T_hNRDIZU2R6iW1V5_fQifM91zHBIF3GFBRy1TBxDo0lQmMlp1eYaGFNwqzkAIYEYP2O8PGKwJ4CSin8LfUWmvBOfCk4uH7VZZ5vSJSA0Lw8rF-AsrHSLOr9A4vR0QqiO4Yrr8xhE456kL6mh73zm5eOc9ElDRq9RUhk7jqYGbUeAHgdPldb7G4UmeM4C-zvEAI5onfZvTgqiNGtazaVZIVQ7yU5Ro0nLsewQpyfPVJ1r_ATE4LvEqUDb8yEartO7fG2JFqE-ayD-qEvXXHXtPdvbkAmQz2LRdstD0P8plXtDvy4DSWRHfmtvOGyb4L3TgTEzzF1E9YZvvYc9r3yArCEHY1GNYP8AtOZLWBp2hIvjXwymouv7Ikr1cfzkn0aaJlUUNzdj2UiNKQVIslYEKQMojoHVLrM4XFtatq--9lXGY4gh64W3yyREmFJ_k2sFzFZ9VKkxdFYIhz7w7n5vw84oiDUgOnEeW4wVdAsDX0CWTy_NCbiZe9Ep_fLx-Hp5yrA7SG9imsUO201RUH3WDc1F7YkOhFuVcAeV4WP9jSZui_fHYNyy3vlILKCOahOelyQXQt_pKEeuV938wLQB0auxmHbHzcA2REQL39_FYDxJD3Mcmwirxt5hb8h5UJKV_CBxWVpf56mYJh3kBziLlCj8RrUV9LH1UEseVkl3GbPMlKGAwVVQNnyQYOlfqWNdokptlzqeFCGaj3ssPDP8sSPMp2_87LwN9kPr1q6jtGAG7x77joc_PFW2oQJqBGsjGBwQfoCGnfUXC8ain6EjcN3jnQcf8QZwWA9N8Zqy8jb4_y9FqOy1nTdPHlxhbnsk9AT9s5iy_F7IDQxRnwT69JTjV6-BreyKTWv5VUWh56brQq1_ZxDywxd07uQxPlsGrGaLyrb3XdzyA9ouJy9oc8Vbe6KLsadc6lHQLBuF0LRDoWe68Js0sglwtAdiTKGQBiVq1sia-1PwvQ0TUQZyUJ4g-KzOkb80wuujVy0Ft9GXtkXj_oB88i77hDnwOQ4BADCvDI_bN4pG0Nf3Rvpxb2KRzwNUzYIMq0gvOiBNo2-kPs5lajc439Fg2uL8-EeVvDEdkAsFB9uwKALRkrcMFiYYMJ1l28eR3f4L9KYGLuvQI2D2MUnT2Ergn3e05gVdAEHSAEuVN-Fw-5I5bpDNW9tcvNvvl4BqHoER5e5BVBSEVokPnpqqq9xeHKFlzMkBWgUjiikt4o96EIvfsBTfI2DNFWEQjxpAgOATG_nUagoSEp5TDTqMM-Vr_Mgcs9L04DL9jrG7GJusO2cRtCj\",\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"Analysis Results\\nCase Analysis: Early-Stage, HR+/HER2- Invasive Ductal Carcinoma (BRCA1+)\\n1. Case Summary\\nThe patient is a 45-year-old female diagnosed with early-stage (T2N1M0), high-risk, ER+/PR+, HER2- invasive ductal carcinoma. This signifies a localized tumor measuring between 2-5 cm with involvement of 1-3 axillary lymph nodes but no evidence of distant metastasis. The key molecular features are the expression of hormone receptors (ER/PR), which is a therapeutic target, and a germline BRCA1 mutation, which confers a specific DNA repair defect and provides another major therapeutic vulnerability. Her premenopausal status is also a critical factor in selecting the optimal endocrine therapy strategy.\\n\\n2. Actionable Events Analysis\\n| EventType | Genetic/Clinical | Explanation | Targetable | Prognostic Value |\\n| :--- | :--- | :--- | :--- | :--- |\\n| **ER+/PR+ Expression** | Genetic | The tumor's growth is driven by estrogen and progesterone. | Yes, with endocrine therapies (e.g., AIs, SERMs, OFS) and CDK4/6 inhibitors. | Favorable, but recurrence risk exists. |\\n| **Germline BRCA1 Mutation** | Genetic | An inherited mutation impairs the homologous recombination repair (HRR) pathway, making cancer cells highly dependent on other repair mechanisms like PARP. | Yes, with PARP inhibitors (e.g., Olaparib). | Both prognostic and predictive of PARP inhibitor benefit. |\\n| **Node-Positive Disease (N1)** | Clinical | Cancer has spread to regional lymph nodes, indicating a higher risk of recurrence compared to node-negative disease. | Yes, indicates the need for adjuvant systemic chemotherapy and radiation. | Higher risk; a key factor for escalating adjuvant therapy. |\\n\\n**Interpretation:**\\nThis case is defined by two major, targetable biological features: hormone receptor positivity and a BRCA1-mediated DNA repair deficiency. The node-positive status categorizes the patient as having high-risk early breast cancer, justifying an aggressive adjuvant treatment approach. The treatment strategy must therefore integrate therapies that address all three factors: endocrine therapy to block hormonal signaling, a PARP inhibitor to exploit the BRCA1 mutation, and adjuvant chemotherapy to eradicate micrometastatic disease.\\n\\n3. Treatment Options\\n| Event | Treatment | Evidence | Evidence Summary | Previous Response | Warnings |\\n| :--- | :--- | :--- | :--- | :--- | :--- |\\n| **Germline BRCA1 Mutation & High-Risk EBC** | Adjuvant Olaparib | **OlympiA Trial** (Tutt, A.N.J. et al., 2021 [PMID: 34062114](https://pubmed.ncbi.nlm.nih.gov/34062114/)) | In patients with gBRCA1/2 mutations and high-risk HER2- EBC, adjuvant olaparib for 1 year significantly improved invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) vs. placebo. | N/A (Initial Treatment) | Anemia, fatigue, nausea. Should be administered after completion of (neo)adjuvant chemotherapy. |\\n| **ER+/PR+, Node-Positive High-Risk EBC** | Adjuvant Abemaciclib + Endocrine Therapy | **monarchE Trial** (Johnston, S.R.D. et al., 2020 [PMID: 32954937](https://pubmed.ncbi.nlm.nih.gov/32954937/)) | In patients with node-positive, HR+, HER2- EBC, adding 2 years of abemaciclib to standard endocrine therapy significantly improved IDFS. | N/A (Initial Treatment) | Diarrhea (common), neutropenia, fatigue, risk of VTE. Requires monitoring of liver function and complete blood counts. |\\n| **ER+/PR+ & Premenopausal Status** | Ovarian Function Suppression (OFS) + Aromatase Inhibitor (AI) | **SOFT/TEXT Trials** (Francis, P.A. et al., 2015 [PMID: 25495490](https://pubmed.ncbi.nlm.nih.gov/25495490/)) | For premenopausal women, combining OFS with an AI (e.g., exemestane) resulted in significantly higher rates of disease-free survival compared to tamoxifen alone. | N/A (Initial Treatment) | Symptoms of menopause (hot flashes, vaginal dryness), bone density loss. |\\n| **Node-Positive Disease (N1)** | Adjuvant Chemotherapy | NCCN/ASCO Guidelines | Standard of care for node-positive breast cancer to reduce the risk of distant recurrence. A taxane- and anthracycline-based regimen is typical. | N/A (Initial Treatment) | Standard chemotherapy-related toxicities (myelosuppression, neuropathy, fatigue). |\\n\\n**Clinical Perspective:**\\nThe standard treatment pathway for this patient would begin with surgery (lumpectomy or mastectomy) and axillary lymph node dissection, followed by adjuvant chemotherapy (e.g., dose-dense AC-T). After chemotherapy, three powerful systemic therapies should be considered. Based on the OlympiA trial, one year of adjuvant olaparib is indicated. Concurrently or sequentially, endocrine therapy should be initiated. Given her high-risk, node-positive status and premenopausal age, the optimal endocrine strategy is Ovarian Function Suppression combined with an aromatase inhibitor. Furthermore, the monarchE trial data support the addition of two years of the CDK4/6 inhibitor abemaciclib to this endocrine backbone. The decision to use both olaparib and abemaciclib must be carefully weighed by a multidisciplinary team, considering cumulative toxicity and the patient's performance status, as there is limited data on their concurrent or sequential use outside of clinical trials. Adjuvant radiation therapy to the breast/chest wall and regional nodes is also a standard component of care.\\n\\n4. Multi-Target Opportunities\\n| Treatment Combination | Targeted Events | Evidence | Summary |\\n| :--- | :--- | :--- | :--- |\\n| **Adjuvant Chemotherapy -> Olaparib + OFS/AI + Abemaciclib** | Node-Positive Disease, Germline BRCA1 Mutation, ER+/PR+ Signaling | **OlympiA Trial**, **monarchE Trial**, **SOFT/TEXT Trials** | This multi-modal strategy targets the key vulnerabilities of the tumor. Chemotherapy addresses proliferation, olaparib exploits the HRR defect (synthetic lethality), and the endocrine/CDK4/6 inhibitor combination potently suppresses the ER-driven growth pathway. |\\n\\n**Analysis:**\\nThe most promising strategy for this patient involves the sequential and/or overlapping administration of therapies targeting distinct oncogenic pathways. The combination of a PARP inhibitor and potent endocrine blockade (OFS + AI + CDK4/6 inhibitor) after standard chemotherapy offers the greatest potential to reduce the high risk of recurrence in this patient population. While each agent is supported by Level 1 evidence from its respective pivotal trial, the optimal sequencing and safety of using all of them in concert is an area of active clinical investigation. Close monitoring for overlapping toxicities, particularly hematologic (from olaparib, abemaciclib, and prior chemotherapy) and gastrointestinal side effects, would be critical.\\n\\n### References\\n1.  Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., ... & Roch\u00e9, H. (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *New England Journal of Medicine*, *384*(25), 2394\u20132405. [PMID: 34062114](https://pubmed.ncbi.nlm.nih.gov/34062114/)\\n2.  Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., ... & Goetz, M. P. (2020). Abemaciclib in High-Risk, Early-Stage, HR+, HER2- Breast Cancer. *Journal of Clinical Oncology*, *38*(34), 3987\u20133998. [PMID: 32954937](https://pubmed.ncbi.nlm.nih.gov/32954937/)\\n3.  Francis, P. A., Regan, M. M., Fleming, G. F., L\u00e1ng, I., Ciruelos, E., Bellet, M., ... & Goldhirsch, A. (2015). Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. *New England Journal of Medicine*, *372*(5), 436\u2013446. [PMID: 25495490](https://pubmed.ncbi.nlm.nih.gov/25495490/)\\n\\n***\\n\\n**Disclaimer:** This report is for informational and research purposes only and does not constitute medical advice. The information provided is based on the patient data supplied and current medical literature. All treatment decisions must be made by a qualified clinician in consultation with a multidisciplinary tumor board, taking into account the full clinical context and the patient's individual circumstances and preferences.\"}],\"role\":\"model\"},\"intermediate_data\":{\"tool_uses\":[],\"intermediate_responses\":[]},\"creation_timestamp\":0.0},\"expected_invocation\":{\"invocation_id\":\"e-ae5ccab6-6c5f-4d71-af28-cbe466f4bb35\",\"user_content\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":null,\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"45-year-old female with invasive\\nductal carcinoma, ER+/PR+/HER2-,\\nBRCA1 mutation, T2N1M0\"}],\"role\":\"user\"},\"final_response\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":\"Cs8bAVSoXO61CxK-5QoaihFRovk-NUxxk9lYX2dOPDXRPeYD4pqv6qE31UCnnPsvxYJR688sunwH9mGJ4QIOfW6akze2JMMoQwW9YeBow3B1IClLN1IVswupu5Cs8J8EGRM7h_XsLY1xRcelfE0B21l3GlbL9HK7hr7TD11IERfzlGSWovW8GkrapIOKosDlIqKbTJ2BIae1pBxh6R9QZhSHu_S1SZAdDr0GMM_bkMyI23PUoNBa31rcwVKyFGZzR8--iBliCccRvGIKTApgoz27KyxyYzvVxnuZFXlrD7d4VjgXVM9KW_UMqnPFkDTGIkZD-8sRxeW5E0VOh88XG4gy61MoCLYHkegvr9bm23hc9vl14pg029lvlZ6FkIemb9yELe6qvtp-RD6In6T30655ZGXGWjfiQ_Hfmu0aBMq7TUiBr4OjQ_FUDwVA614AlTesv6VDtT4Ia_HapDDfAOe4w07ReKe4gjfpREKB8PrtKDWAzDSe9RWznRODDiWYgvP6KsTYuHkSf8lBd3DpqHapIdCuUfgUVrI-m6RZu1I66BDSDjeLHd6HaIuuMq-CAkxR9GHQhgCvY7hRUZ54S9wmPECwLMpxqoNzlJemZ9EL-WZu6UC9hMsSn2g6CmY7_CJM7Exuyeez8Z8DgCzmC6AQ0B78gJF8FgoZzIrRPSXyNnjRh0ZTcqHU1vm1IafkFRxuftepV99DzTZAqu2LkMG6mVF5rihFejGZtMhUn5Ls0CciyHJidnjdJHW1e0sSXPDQWM-EA7iSi0ufFLobvk2J35rhcZb8QY08MXeZlTw5VnQ_nFj5u2j0DpL1h-JUB6iaIQbOur2OyxtjCr13vkjMVjg4evcbiYc5F1bef4db3gXhOzrLTYGjvMM1HLcnRiKsf7zoH0XGDwp_zprBy8pts2qzRvg7_Diu60Fws1--cJLPAHm_m_YCcrONyHmJ7GOTiCDm7HX58GJxwguh-IeOlbn2Ak-zKpvp-3q0R3MQ6nrH7IOHj1gDqVgZoKTy6eCnLXQGwnJS3xze1ak1kZUizncI3LNaHw9cbM_WBWLVm30_wu3lRwibHKtFbfyXXJKzBJStrWQJgwO8c88Tk4eUl3_BjdGKaNoIj_k8kSgLwfS5J8PEHRQqW9cexCv9VNRt1Z4MX5ybmCQdcnmggUneEvNtuGhsHtipPtXl8RKCDscvHpmgd8d69eoySDMV-fn-gaNxosMs5QNO1pahPUtmTwd6VnjFGxonbsoX7V2iyBx41znEhQCg6BHu9zaVCbjqTanyknvk0BKpVPW6Dwt9aXCXIi1k6QSn5WKHWhOkKqu512Gi-K_kX-M7VLdN6Xb-P672yjtSMmBiJ2s9xAuispQpfb3ovxsEryfv_z2i7mcwJPW_5ceit3q8j7VzunP1VuJ60ObEZt1NpIvR3ZyL9aWThjhY3Y6bSD3FX6kKrtqYEh1C9XB_EPMKobcOfM4oikKWPK5A-X1OyjzaZ_ED0do4q0VfSwZgmYOWKVXHvtuQ1H0LOcslpkSbSJG8sDnMI0KGVNH8s6FqoBRfROqziLfg7I6TEd9b2HVcF9XuCoL75VsaJN-WLgIhuNOdZ069ODb1vBfG6sFZk1_pxRzGi3w_v9cYfyZqpsy7OKuWeV3FEV64AznHnubIrL2NmcY_FWLjT6dkoNJC5vWMZIRl1m8_9YjdEezPz5g_xHTxE1qmGI5lzHPjXqCbVMCI0TW1a-IpKSw1kkJhLbb7s5X-mC6jlY130AiYPLZINhZ7QKijMv-vNOvoIjB6Ye6m3HxedQObA48TtYNtsykv3HkebtmGQeLaaJspSdWbGZWrDO4YlCui7I_Eh59SifirJQ3zS8FViNzZSOHbVW3ZNNp-ZwrVY-T1AECeeA4MUxoEpcQYA9i0SSOs8RKRgc8y3S6WIUxc9EpqZixSvlJsK5xKLgkp7HNihOolm9kW6eYB4WDFPsoNYIMskogEzGDLMMXTQJboftoAzmiqgg-ZrwTP7rdkpk4UREvl8Cx28Iv1hKXwSKfqJJrO9cahtKkyYmTPAhayLTsrEPDd6JTJPEKM4BCbWs7qg81fOa1wPHQSTbsNYWVFREwggRfu3PLigwg582epsBWGyPrGaQT_TjERuwTF_LH7Cagd9b5x32FBAwY0t5r__yW1-e5YTNN6V-__VZdke9z6ndDpuIJ3Rw61PUcuJ1uYITIr9pjiH8e0tnILsmakvKQNxN3Pdoc2EZOJm4acNJO63WfIXzKfx2ObYDdr8S_CdAvaISNAYyjzjIMOg5tJFBNSfiIsVCtDDswlfgWVP5nJpcBN99Emcr8QP3SMhBolsgF45Xwpu-YswzNX5iwM6Pc1JnQ8ri85W-jp4zEivyAbcH18mtMukbVZGyDaPfSG3EaXy62t6w03hg1nH_5jy-4pAI5zmp75sW4cFiKhEsofM-5fiaVZQ59WdKhYiZyjTQdncc9yIYN1ydqyxAuuJd65qqf2gtd80O_YnTDolFLiILrO3NHNp6gBp4mKuwmcmEIWZrkwhKAvet6yJhwkI4k3XEygDyjWRIas-25y1AWQG6H3Me0EXJ9RK0nTgk7xcJ2DnvQgmp103GUM2-HeZHFkvqsTe3GKMs0cBeXuNAk0OFUM4p8tYq2o4J9xlGL9jau83nSh7ErUq6rPEjM0W4PeA0basYfkXNuyO1Nd-j0DLEO9_WCbAaU5zwApIQaIja-exwddJ0jD1c-jgROUBOju_NF6zxk5KTAgJxgfAwro4L57q3fhpWvi5MX4W9B2qD8S89nAQdnede-5_q_MFXLjskHw0_8Tv15fswfNwzDjtfO8wvyQpVepMhBNLXuQMMM8EA94jTLknoeoZMb5m86vorA9wYHjSWRIbPcHIV26_e9RjTB8TWMduaVwXb8CACCJj5wOJFw2SwSwKOS5MucPAXQ-EKB0qMkYQ0jKsyqaQL4zau9pkEIbuUFpxHulBdyKXb6M29EjRv1ZAhdFktAul0b_Pezuz3OIoDp7H6ArLWipyn5rb9nBwAcKXvivJX3-8APye6HGcEhX6nhpomYxKTpTrBJ3Jb-ClA_Qlq3_P-iYR3YjuUW_qzwKF2GVdAyHrWPlrXGG2x99BYDSTpV42kDmQHYYarfRNpuWtT68f6FtgGiqwwfWI1ZfQhGGpNZPUFwXRRl01bQsw4hn2Nr-C_dCxwupBO0PvXeluytn2D5pKWmx3ktRE68bwYIsLEcdXH7mxjrZfkvkghNCxZSkHbHiRPR48pXjfdQ40S3sIiT2DgFU0z9ibpoS63ilZZUEhgZQcgbuQ43M9KQCb-9fUjnlyD9zJdSVEpSmL3khl-3fP89UWBDv1Bu_Ut2N7sb5-WeQHNKS_A8musqgvX5zrmY8yrIMqNdZE8bWH31geOhTWb32vy5_sRF6F5HJt00z5QpN_i4OznlmSjDI6Vh0w2AAJrZ9l6Egi6K8IwQ0vssbsNCUqfqLddeNOEg6iGYL9Ko0QzRw1bVcojMyQEjyJ_TKSVN3wNxE57wJa8YXM-_uQu65GLBiapRPkVOPOywovIox1Pj_WPsC-hWYU3ZJUYCwjhlYH74s3ynnc8MbrELXscu-on2MGmwjLHyFl622hVtCcTqPm7ob10_tC5hyq3z480lAT_EOMmsbFIGw5L0IkHckOdguz79YgFWLdD9BqvBjzmrsHpCFoOMrMMz0pOBLl_N084GPOvdFLLcHo1OV8edXMluBz7CLBnTaXMfWeS5C3C21Bxj1ZqjrW0Y6ZBVb3T--AE55oHAeppNsewkj2O6eKtOvbC7UTMvnawqVbzCaWmgABhEUoy_Nl2HR_iuX-Jot6ALXvW3PMJ4IAiI3zITv_1HJpc2X89TAwKj5zN8sBj93nB8j9kZQDYklNC0kBUprFT5eoqXUMliNFNLI1IObCQMrj9J3kk-B-EojpUTeEbg4JYAF77rBzBguLTMGSCgbUU-5X7IOH_IJmXOqkGOd8pZJFpd4HXwokPYedIh4I_JyC2SPq6q6lD14s6V3wcGz6uMYtCi3QGznBKPppUErhLqdjFtZ-XePKdlgXKkJaqtkEYo_-LujUsJeJAVJc5SFHXIMfB8df9ant3YsIygHfRNazL67CtXIVbPQq2nIU6--U-5Xzme50Khn2xWSQK5XfrMWOqIpMfArp5FE9r0nU_h4C5BKB58xiiJz8deqACm-ks62bHsc5yFEf8qnGkwgJBVUiEGZpOzyOzfrHRltjwJ6XkGeZKvmYfG_NjVq2zdf1StvDc6YyVfEWVmx8yQMTyX3ClZpJboc62ewPMbvjbc2kbdeml-WdbOIQnE_CW4h5iopy_q43TeqRAENvfDwoI1mzqpS5hZQK28sUgvoHQ8VhCWf-YlyW286nhAv90OMTesTow3WHz4aimkcHg-PCmyTBbeMEwd4dvC_oQ3pBjVr7YfOnHY5bQXqIcZRk7Dlo9-luLS7JLanq6ibDZADV4etEwkACVQec-sNZ-EmfuRjnpkfajLgEf3-y4NBLZcjBG3TZchyse_C7J2JU86nmYs83myej_nTY-kq46UrS-P0h8hsf9yR-hv8dTQ-Sc9Ewjy9XmraNrmPFJnyx_c7w4H7jV2r8m16vQ2-IV_TLw4UPwM1BxtAqCO_Fh91WQ_dEkIqFbHqrvxOeLCMJd9TEt8WsaTxIht1BK9nxjB9BgJAU0Q1vQBmOvDVEZhZwsMTuw==\",\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"Analysis Results\\nCase Analysis: ER+/PR+/HER2- Breast Cancer with Germline BRCA1 Mutation\\n1. Case Summary\\nThe patient is a 45-year-old female diagnosed with stage IIB (T2N1M0) invasive ductal carcinoma of the breast. The tumor is hormone receptor-positive (ER+/PR+) and HER2-negative. Germline genetic testing revealed a pathogenic `BRCA1` mutation. This combination of factors (hormone sensitivity, BRCA1-mutated status, and node-positive disease) defines a high-risk profile with distinct therapeutic vulnerabilities that can be targeted with specific agents. Treatment considerations will involve standard endocrine therapy, likely in combination with a CDK4/6 inhibitor, and a PARP inhibitor based on the germline mutation status.\\n\\n2. Actionable Events Analysis\\n| EventType | Genetic/Clinical | Explanation | Targetable | Prognostic Value |\\n| :--- | :--- | :--- | :--- | :--- |\\n| **ER+/PR+ Status** | Clinical | The tumor expresses estrogen and progesterone receptors, indicating its growth is driven by hormones. | Yes, with endocrine therapies (e.g., AIs, SERMs) and CDK4/6 inhibitors. | Favorable, but risk of late recurrence exists. |\\n| **Germline BRCA1 Mutation** | Genetic | A pathogenic mutation in the BRCA1 gene, leading to deficient homologous recombination repair (HRR) of DNA. | Yes, with PARP inhibitors (e.g., Olaparib, Talazoparib). | Both prognostic and predictive. Associated with higher-grade tumors but confers sensitivity to specific DNA-damaging agents and PARP inhibitors. |\\n| **N1 (Node-Positive)** | Clinical | Cancer has spread to axillary lymph nodes, classifying the patient as having high-risk early-stage disease. | No, but it informs the aggressiveness of adjuvant therapy. | A key indicator of recurrence risk and prompts consideration for more intensive adjuvant treatment regimens. |\\n\\n***\\n**Interpretation:**\\nThis patient's cancer is defined by two primary targetable pathways. The ER+/PR+ status makes it susceptible to endocrine therapy, with CDK4/6 inhibitors being a standard addition in the high-risk setting to improve outcomes. The germline `BRCA1` mutation signifies a deficiency in DNA repair, creating a specific vulnerability to PARP inhibitors. The node-positive status elevates the patient's risk of recurrence, making her a candidate for more intensive adjuvant therapy, including consideration of the PARP inhibitor olaparib as established in the OlympiA trial.\\n\\n3. Treatment Options\\n| Event | Treatment | Evidence | Evidence Summary | Previous Response | Warnings |\\n| :--- | :--- | :--- | :--- | :--- | :--- |\\n| **Germline BRCA1 Mutation** | Olaparib (adjuvant) | **OlympiA Trial** - Tuttle et al., 2021; Geyer et al., 2022 [NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2105215) [PMID: 34111394]; [Lancet Oncology](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00412-6/fulltext) [PMID: 35944577] | Adjuvant olaparib for 1 year in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer showed significantly improved invasive disease-free survival (IDFS) and overall survival (OS). | Not Applicable | Anemia, nausea, fatigue, neutropenia. Small risk of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). |\\n| **ER+/PR+ Status** | Aromatase Inhibitor + Abemaciclib | **monarchE Trial** - Johnston et al., 2020 [JCO](https://ascopubs.org/doi/full/10.1200/JCO.20.02514) [PMID: 32955575] | In high-risk, node-positive, HR+/HER2- early breast cancer, adding 2 years of adjuvant abemaciclib to endocrine therapy significantly improved IDFS. | Not Applicable | Diarrhea is very common and can be dose-limiting. Neutropenia, fatigue, risk of venous thromboembolism (VTE). |\\n| **ER+/PR+ Status** | Aromatase Inhibitor (AI) or Tamoxifen | **ATAC & BIG 1-98 Trials** - [Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61625-8/fulltext) [PMID: 19010018] | Landmark trials establishing the efficacy of AIs (anastrozole, letrozole) and tamoxifen in the adjuvant setting, reducing recurrence risk by ~50%. | Not Applicable | AI: Musculoskeletal pain, bone loss. Tamoxifen: Risk of endometrial cancer, VTE. |\\n\\n***\\n**Clinical Perspective:**\\nFor this patient, standard-of-care adjuvant treatment after completion of any necessary chemotherapy and local therapy (surgery/radiation) would involve endocrine therapy. Given her high-risk, node-positive status, the combination of an aromatase inhibitor (assuming she is postmenopausal or will undergo ovarian function suppression) and a CDK4/6 inhibitor like abemaciclib is a strong consideration, based on the monarchE trial data.\\n\\nSeparately, the OlympiA trial provides compelling evidence for 1 year of adjuvant olaparib. The patient meets the trial's eligibility criteria (node-positive disease). Current NCCN guidelines recommend considering olaparib for patients like this. The sequencing is important: olaparib is typically started after completion of chemotherapy and radiation and can be given concurrently with endocrine therapy. The decision between offering abemaciclib vs. olaparib, or how to sequence them, is a complex discussion as there is no direct comparative data. This should be reviewed by a multidisciplinary team, considering the patient's specific risk tolerance and potential toxicity profiles.\\n\\n4. Multi-Target Opportunities\\n| Treatment Combination | Targeted Events | Evidence | Summary |\\n| :--- | :--- | :--- | :--- |\\n| **Aromatase Inhibitor + CDK4/6 Inhibitor (e.g., Abemaciclib)** | ER/PR Signaling, Cell Cycle Progression (CDK4/6) | **monarchE Trial** [PMID: 32955575] | This is a standard-of-care combination for high-risk HR+/HER2- early breast cancer. It dually blocks the hormonal driver of cancer growth and the cell cycle machinery, preventing proliferation. |\\n| **Endocrine Therapy + Olaparib** | ER/PR Signaling, Deficient DNA Repair (BRCA1) | **OlympiA Trial** [PMID: 34111394] | In the OlympiA trial, olaparib was administered concurrently with standard endocrine therapy. This approach targets two independent vulnerabilities of the cancer cell simultaneously. |\\n\\n***\\n**Analysis:**\\nThe most evidence-based strategies for this patient involve leveraging both of her tumor's vulnerabilities. The combination of endocrine therapy with a CDK4/6 inhibitor is a well-established, guideline-endorsed approach for high-risk HR+ disease. The addition of a PARP inhibitor is also strongly supported by Level 1 evidence from the OlympiA trial.\\n\\nAs there is no direct evidence comparing (Endocrine Therapy + Abemaciclib) vs. (Endocrine Therapy + Olaparib) in a BRCA-mutated population, the decision requires careful clinical judgment. Many institutions would prioritize the PARP inhibitor given the profound survival benefit seen in OlympiA for this specific genetic subgroup. The combination of endocrine therapy and olaparib is well-tolerated and targets the foundational genetic vulnerability of this patient's cancer.\\n\\n***\\n\\n### Disclaimer\\nThis report is for informational and research purposes only and is not a substitute for professional medical advice. The information provided should be reviewed and discussed by a qualified multidisciplinary tumor board and the patient's treating clinician to determine the most appropriate and individualized treatment plan.\"}],\"role\":null},\"intermediate_data\":{\"tool_uses\":[],\"intermediate_responses\":[]},\"creation_timestamp\":1754690980.953209},\"eval_metric_results\":[{\"metric_name\":\"tool_trajectory_avg_score\",\"threshold\":0.2,\"judge_model_options\":null,\"score\":1.0,\"eval_status\":1},{\"metric_name\":\"response_match_score\",\"threshold\":0.3,\"judge_model_options\":null,\"score\":0.6587677725118483,\"eval_status\":1}]}],\"session_id\":\"___eval___session___840799e2-4ca3-4f6c-9b4a-ac65cc900378\",\"session_details\":{\"id\":\"___eval___session___840799e2-4ca3-4f6c-9b4a-ac65cc900378\",\"app_name\":\"capricorn_adk_agent\",\"user_id\":\"user\",\"state\":{},\"events\":[{\"content\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":null,\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"45-year-old female with invasive\\nductal carcinoma, ER+/PR+/HER2-,\\nBRCA1 mutation, T2N1M0\"}],\"role\":\"user\"},\"grounding_metadata\":null,\"partial\":null,\"turn_complete\":null,\"error_code\":null,\"error_message\":null,\"interrupted\":null,\"custom_metadata\":null,\"usage_metadata\":null,\"live_session_resumption_update\":null,\"invocation_id\":\"e-05464017-10cc-4d26-8ec4-05e4cb204813\",\"author\":\"user\",\"actions\":{\"skip_summarization\":null,\"state_delta\":{},\"artifact_delta\":{},\"transfer_to_agent\":null,\"escalate\":null,\"requested_auth_configs\":{}},\"long_running_tool_ids\":null,\"branch\":null,\"id\":\"285b5b00-47a9-4c6f-bb35-5d91684a4d06\",\"timestamp\":1754695837.369574},{\"content\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":\"CsopAVSoXO67RVak5Uj_3wb6GZ0DxdgNyWxkrFjLsb9aZMZBdx-08piqz77KtmCyASyHFFp1Smmsh7_3l6zBG-19lMutdKZUCcdQySuP8MGoa1DfbSYdB-DZs2AndP0g_IVGcNjnjJfEmBRFyedxtPfH2YkfIp4yZax_yHscuVXgtdZ-nunONoMrQX-0imheMj4xV_9OT5Mr7AnEnKY2gEMCSFBCLJSn_5m0VYo4rVZNccw8y1m1MCVYfkBGesRGFYoVvoMsh4gRd7nDTuIXHAJP3bG6tCv2-C6Bw6lvV9P7noTzoZ0lh-v9ZlxYZCZafBl6NpR6kGebkg3-3IXdZBIBB_iMmb7nkFKg1moIejrf25ckLOoVZuW7oZZ3Q8RhlRdv9b9mEa-6blONSjdmQcCY20Kpa3M6PyeEjI7rKtmBCo9p-Lz2WmSoOF5glfT7c30CA5lHt1Z7WaVvkR0tmgPmkyovC4TYWLh_aYBmSc-3JJa-qJ2D65U3yuQP3epwHjX_ystfpQQCJThwuJ8bnRaSyIWDw43zRY2xUZDYWID5P0A4aMJTyygsQ8qIaSFIOfBCvR6BSdra2vin7jWw2kDKhysh_fiTKXIN1oCTmWtskXcIZuJB_5irGw2jTfeqvE1gyDAwExnQ8TxsFv0MeFpKGCyQoiBFQLKdLU3NAqgeFSGy4PpurG5s4Ca1jXp1PGrdn4gFAYgv7nnWlbRpMgGT7RbBRfBloQTyHI0n-m8MCRK3y_RclFN5eX8NE2FAtUbmmwimEs0T3UMoVJ3gATDu4-lutgZ_7mJupzyt3UYZl7cQ2KQjI72y-ZXWc47RcSeKjb2DIXF9-c1RO3WZ4b5L0QswHI3QUYwfrWu3WBwihHICqWIXiApjXZgbL211h8eis-JFYs-SGuNkQF1xdIbmKh06dEFd9pc02syxe29Tap7z9zcExWhMKdpFAR9hadcV_rXVT4p8BED5NsZiAsMjbACAUqfoIUC17UDLNWaOA-ObYhfpCguaHOPFC8VxWb0F7YcPTycfF7K4VgOk3UpvpVsf4mTpCPrMbN4UIC8zTOzaOKsWbuXkZw3tDmVvCmq16TVMbY-G9q24Z3ysEktnRNrd24JumzGO-hYutBk2nCZHjpP-Qw4fC4gJ0lCXsRKMPwLfr89XkERLRbFrt09Hb6Dx_XIHNhtLQQ_OI_rnO5ICgiRzFpIGG2AMLibXVh4Aerq5-wQlVmYPfKocXJBp37vzBNrN0sQ-ykeOGCBddOd35_IEbXlEYTmiSfSsFWclorXeqTE-rz3z-MKJ46CX0C8qG2jWOB75F27feFLop1apHwAf5kJQc-FNdYLLaciu3Fjb21ME4751Ir-B_NH2eI8mTQkzobXmff13imVRs5u1dJzYr-g7h0ImCznOufnbvxHcIHFlc_Q9lSwZXmTTT9tHrWBZASuEqsvhvakEBd9GrbLoPpcgcEOh6BjCFDuNVpy4WKSX-1kcVUNPRpXmhTQv0KYwy1lVGRGi-fyorAInmALwXnJgb-hWtbpIMRvB33hebOyKhRHojC1-POcSTZlvNUBUkhGl6XNGFb3Ep0DaOJFZ-Dw7pHhGgf2p6YE14L_-u0zqYADLI4d9pciwWSydy0Lv0HUeqWBrskXlLMuJPW50wtSkDJzqQgveaE2_fl6DiywS80N7GFRvl5rUcN1ECvLf0UgmKtd0VECJJMx82S504NpQEBbDwOXGy5UmYxN1ZB1xwnDWU3oiAU8-1ftdIe-32QLXN2mNBoS-UCKVdNtjm6CHafFXEspp0W2CUEY0Jdl-QTPQ8UgvGgtKSXjU5pEjt7odim8GFgNSXLFvPe5rgEyNkuvUzdY9SqihJyGR1pDnPptfB8W6EV6KYKZcqZkZGCGQ0_UfIrAvwll8Hbc6uC2zQ-thMQ1hgKIO_-hzxs7IHo1Uj_S2h0ii49XoIizAV26YxAVBpr812ZfBGfuWS1APkM-WgorDlDA8du8DOz8eJl0F8H12iWN_OCiZ3spnmUbcDYN90NdfwCuWNa2wh_IdfUB-JS7x1s08bUq_sNDmkV40xvApiURI4G3ITiSRz--A9cMfYkHOutkJV2WFj2tUOTZsFY6Eeh7kr5UgemHm_Cr2pU-WWa7CFOYLx902DBC-NgPAUSIRj1S2O0phK7vyrht-pTEnYW21uar9id_U00URbIcOE5kK4hOb-sy3RIPa6Ry5I3VCJ_is_lgbd543Wd2OEgpbLfGoGjPacXFFJUVJ-vCwTQEHlkN8uix1vzF8T-QMFsn7JKO5chV25dKsjKlSVfzAI6gRlh6pxEnNMP3dFVF2xI81wxG-b1INrXkt0zCuzAV2S7QSnQe5XKD3EOiWOiNkaT_9MXb8dq9bzkdHsZam0bElZ4zeCWaZX5EXt8rk_Cs6zYRNIlKFNWDSallg1Gqv98EhkZFFlGioA7aobEkBo9E8jhbiS4BtPo4EOVsZT1SI3RjG5Zv41XFdWKh23Rjg-JCFC5ViKi-pdPdNTGKKo5uHmNT97Sp8iZsYJicEFz9wyR7wDUFYJfy8Se2uJrNqvR8VbsPQk4vCULAJrhOnDyFplfjpiyvgv4cGa1JYl8Id-APwhwrL2cqD_Zbu8FrGGV_UTc498-D-Gep9dlJbUc7_St2Bvc_lOSeAoan3KSOTnSMqHmKdTo8871EwXVvtdcF4nBghtFnpr4rWobtQW8d1hH6WxTeFF6ULgwilGT87luIJqciT1A5ixZKEoH7AgM7K5jyKeKqzmdBVhyXZPB0ee-0PdiK_S0-ODV9icymBIVYQzPm82dEvwAaY_pYoGaliu2c6_G07yHaz9c7jInq2ML_cTQTnzwiZNwWqC2mWLqHVYlhZPOQcf6rA2g-4dCgIf8Q4hGspswp7HdfvH0YZz03O2CMMQ_FqkObYXfQt68AUxFBhXqtPuKfIWX0DrHiZ4vUpgLCzY9U7KctSnoQGe_P6hW0k-TGYX5t6_SWu1QLZ-K4AZdjO24Ufz3IOoQwPzxzMPRRfl4sfYDwfn5h77sX4QcVRnEp3F9NVnWxZRJzF1ysAKhBU5L9aZ3XXa0TxumfgB4RD6WzI-n3cEdUQ5k9uOdMwl4mNU2l7Sb45TVQJlL-Vz7uwDHIWP47q5vZzX71i6EFOnBfr7HWytpkTb9-YQIi3QffuP53F7zXKQz0_xhkeVLAgeF14qpUIvAGyHgri8EHDaLziNu-L-hWnD8xN823ZRDSkY6-9L9rJzE2LgIWM5dEnJ5ddp6iCXpqn5PneW7-vtf97AKtbu6dswJ933zcHWHfF-g9IO_PRRn1PMwJ1J5JkPXKQgVTQff3ZXvLbXpFGEmlt17ZJBI1DNEOb2MGKbISou0V-8rIbg85porb6z39q-WAESjVlekVT4BDLEHoJjGF23s4VLC8nQvecX4PsZOHaDXOdaPxDeHrmku93nFFSsJFEGQ8e7mUUKQ0xgY0tY77C1FGbG1lDtL2pob0Ncr6qYHtm6qGjxtpXAEmThsMvRCAYfWJE8uDQD3eGUgWQ7xWVSuWgEbQCPoB_yu9dW8gp39zuLGckJoi2eCrLLCPvZRszQJ9yAZvfZYnD31_aYAONWb0BM0ycvkxZvlrt-hv43GtYE2gCB-VWef0vnkC62ogWMrVjcdVgp1s5bkKs-1ousqmEsEnI_6nRanvuEoWjOAI43lal4ZLIseRS6ir4LqBeP3Q5qDK8FT4RrtlDLhii76bZK7bzlUCgmcv2iAginL8gxjyXSeGrhsfFGxVU11iAPJjYBmNVYjIWHb75QcnzZPOm_Bkzcdx9OkdSIElIK8sZTK1hQk0sK5006aegOPCc8OuOFPDt-aJ5T64JEPcSLh1iavf_TGDsFjAi4K8v5oWweOBs7Dt4TxJfeFGioXKaCmYWFnG417i9uw8tKqcIn0pGc4w1BxX55qJwbczpY7EaKMH1vertZEcJLe2c_ZctGoHQY1UvObjFfu-tLgbP9nyLBNFYGc1soOZNryGf8YhwDUi3hJxSs01FX-y0ie_uXe1Fb3TS37Cr8B93QRbAo2q9yGDxnQkJjSRKiDV4k3nNxbqfN2_BERS0UOyVVI_wYCDZc7KZxpOLJ-0sLi2MR37OqlsSntHoONWRwIchb-pNEwpAqs3VOGJNBquIGkXM9D42D_WkNrCWiZCEOWPfuDK_aRhdVRIkeWaj7CREuiaySSPgS29E0JalVK3D3mCHUPA8pFfwNfpPuGm_y2GuVX3EqmjiUn5LWE867L539OsQK6Y8_vTBIUsqeXC2MFcgYjcNlkNmxpP6Vaw0PHQVU04XGewnNAPnqczOm6His5ZlkyWfrH3C9zEw6IG3I2kmo7A-2PPPPk4rY_PZQE427z5DY5xZb5U17XfwIEeJ3cX60neBS_TCVVdSdi8fnXPLu-HCuNZCDkUJq2hXj6BhMuC0hm8Dd8IP4WzEy0KzqAeQT9LICeqdivzRs8YVCLNnix02-V_qhGQ7_RLngBv1A9QzgIj61ceojBOTVHNGJxuvafRWRAT0e_sEgfX1noBGqgKNEyJvxzd0IbWpxkZz6A9I9j-VtdDHVnII__dRL_Oidb15Ht0PIXnenCKY6AEkiEP3W_zffjARSoO1qGAWOe0Q9qIvB9unJCnB6MO4K8lytT5dCNqyZw2G4MNr-wKE5-o47_z364PGdMCjzCB_crE5JDe8yTUwyZJs9J8UewS3FEKKbGLXo0n5cd3c8Kt9R0j-ecY5tRcG9FvyKqn2sIfI-s_p9Z7h_r9Ua8E3awomsaTXCsVs88eSWkcTWRrBHaK7Iuug5Hjl3oFF9OyiOHDr1LNt3OtJXOzjy-SCQyWrncRlWzovR9RKzzgg5fr6sv61s321WTEZLIvl_6pUdOGMQz5zMw9_OCLVUiXmjkAZOTjGZqbVoK3Ej6LYHNL4TW1XtnWe9_XNZ_kIQDM_fDzqzFRGxiMyK2F6oWnjg8R-Vj985FY_kWwEAn1EHYsgErVSEx4pfCeT5i0h6AK-_oQmYplTBh7xdN5w0CY1sM_N_Xax1bYg0qEYq9KgkY2PK2ivsw82XubJMRx9UVx8Myc4QksptMp4QSu9x8FNqjDZykpemje0xghDAB6Ktm8BwqNyUveC1KJNMqsH77Z3fP1WIWgQI2T5p0q7hRbr0ARu-RLlW4u38PXi5Hb4_uSaLZCKIFB7b0PxI8kbrPAEXz6QqwQooIbiEbtaRDoaoMve9skdiU7lXhgxZfkWAlI4wd90sjcyg5HaHuTuIVo04nqCCg6QDOh-q6-nNiRu_DXZ-FL7VCcsFTGoDh5Is3FUts_AcXffo4ueNK8yGmGI2jx6mH4JImF0lnZtPxSsGIDnRgo5eHNlKMJ2fBkpMozMml6v0OVPaoLalI0oLSAj6tjWalb5Wq0odVFLCoJI7NMuyZhZeWkcQ2MLwZ0n6x0QMr_HPT0LeSXyorluiH8Z_usCIv20S56V5axwexjec30THzLQ4UGK_9K0codD4jbMtAYLSQab3WVnco12PaN3mtFFa5P4fVNhymcT2r2gBFfz5WmtGmpCpFcn1TqgJ_WmJrdp5r_XLRwuy0vR1TOGES5eayVtq1LDTf1jFRkUIA-8qc5aaRiA7vgziTcY_O3p4XeznnW3nGZXDYEYl1a00maG10vkXS5K8EqXn8dcrc9bsN7OHc6wBFwjf8SntmCcmwAoCAExtzWvIkfUzvOt6GmCHRk5n8L64v880G8N4AgyXjJrwFmJTed8aPJiYi8uXaWaYiJTMB-7hi3Z4NLnZijxdlnX_QKv0VHovn344qC1T_hNRDIZU2R6iW1V5_fQifM91zHBIF3GFBRy1TBxDo0lQmMlp1eYaGFNwqzkAIYEYP2O8PGKwJ4CSin8LfUWmvBOfCk4uH7VZZ5vSJSA0Lw8rF-AsrHSLOr9A4vR0QqiO4Yrr8xhE456kL6mh73zm5eOc9ElDRq9RUhk7jqYGbUeAHgdPldb7G4UmeM4C-zvEAI5onfZvTgqiNGtazaVZIVQ7yU5Ro0nLsewQpyfPVJ1r_ATE4LvEqUDb8yEartO7fG2JFqE-ayD-qEvXXHXtPdvbkAmQz2LRdstD0P8plXtDvy4DSWRHfmtvOGyb4L3TgTEzzF1E9YZvvYc9r3yArCEHY1GNYP8AtOZLWBp2hIvjXwymouv7Ikr1cfzkn0aaJlUUNzdj2UiNKQVIslYEKQMojoHVLrM4XFtatq--9lXGY4gh64W3yyREmFJ_k2sFzFZ9VKkxdFYIhz7w7n5vw84oiDUgOnEeW4wVdAsDX0CWTy_NCbiZe9Ep_fLx-Hp5yrA7SG9imsUO201RUH3WDc1F7YkOhFuVcAeV4WP9jSZui_fHYNyy3vlILKCOahOelyQXQt_pKEeuV938wLQB0auxmHbHzcA2REQL39_FYDxJD3Mcmwirxt5hb8h5UJKV_CBxWVpf56mYJh3kBziLlCj8RrUV9LH1UEseVkl3GbPMlKGAwVVQNnyQYOlfqWNdokptlzqeFCGaj3ssPDP8sSPMp2_87LwN9kPr1q6jtGAG7x77joc_PFW2oQJqBGsjGBwQfoCGnfUXC8ain6EjcN3jnQcf8QZwWA9N8Zqy8jb4_y9FqOy1nTdPHlxhbnsk9AT9s5iy_F7IDQxRnwT69JTjV6-BreyKTWv5VUWh56brQq1_ZxDywxd07uQxPlsGrGaLyrb3XdzyA9ouJy9oc8Vbe6KLsadc6lHQLBuF0LRDoWe68Js0sglwtAdiTKGQBiVq1sia-1PwvQ0TUQZyUJ4g-KzOkb80wuujVy0Ft9GXtkXj_oB88i77hDnwOQ4BADCvDI_bN4pG0Nf3Rvpxb2KRzwNUzYIMq0gvOiBNo2-kPs5lajc439Fg2uL8-EeVvDEdkAsFB9uwKALRkrcMFiYYMJ1l28eR3f4L9KYGLuvQI2D2MUnT2Ergn3e05gVdAEHSAEuVN-Fw-5I5bpDNW9tcvNvvl4BqHoER5e5BVBSEVokPnpqqq9xeHKFlzMkBWgUjiikt4o96EIvfsBTfI2DNFWEQjxpAgOATG_nUagoSEp5TDTqMM-Vr_Mgcs9L04DL9jrG7GJusO2cRtCj\",\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"Analysis Results\\nCase Analysis: Early-Stage, HR+/HER2- Invasive Ductal Carcinoma (BRCA1+)\\n1. Case Summary\\nThe patient is a 45-year-old female diagnosed with early-stage (T2N1M0), high-risk, ER+/PR+, HER2- invasive ductal carcinoma. This signifies a localized tumor measuring between 2-5 cm with involvement of 1-3 axillary lymph nodes but no evidence of distant metastasis. The key molecular features are the expression of hormone receptors (ER/PR), which is a therapeutic target, and a germline BRCA1 mutation, which confers a specific DNA repair defect and provides another major therapeutic vulnerability. Her premenopausal status is also a critical factor in selecting the optimal endocrine therapy strategy.\\n\\n2. Actionable Events Analysis\\n| EventType | Genetic/Clinical | Explanation | Targetable | Prognostic Value |\\n| :--- | :--- | :--- | :--- | :--- |\\n| **ER+/PR+ Expression** | Genetic | The tumor's growth is driven by estrogen and progesterone. | Yes, with endocrine therapies (e.g., AIs, SERMs, OFS) and CDK4/6 inhibitors. | Favorable, but recurrence risk exists. |\\n| **Germline BRCA1 Mutation** | Genetic | An inherited mutation impairs the homologous recombination repair (HRR) pathway, making cancer cells highly dependent on other repair mechanisms like PARP. | Yes, with PARP inhibitors (e.g., Olaparib). | Both prognostic and predictive of PARP inhibitor benefit. |\\n| **Node-Positive Disease (N1)** | Clinical | Cancer has spread to regional lymph nodes, indicating a higher risk of recurrence compared to node-negative disease. | Yes, indicates the need for adjuvant systemic chemotherapy and radiation. | Higher risk; a key factor for escalating adjuvant therapy. |\\n\\n**Interpretation:**\\nThis case is defined by two major, targetable biological features: hormone receptor positivity and a BRCA1-mediated DNA repair deficiency. The node-positive status categorizes the patient as having high-risk early breast cancer, justifying an aggressive adjuvant treatment approach. The treatment strategy must therefore integrate therapies that address all three factors: endocrine therapy to block hormonal signaling, a PARP inhibitor to exploit the BRCA1 mutation, and adjuvant chemotherapy to eradicate micrometastatic disease.\\n\\n3. Treatment Options\\n| Event | Treatment | Evidence | Evidence Summary | Previous Response | Warnings |\\n| :--- | :--- | :--- | :--- | :--- | :--- |\\n| **Germline BRCA1 Mutation & High-Risk EBC** | Adjuvant Olaparib | **OlympiA Trial** (Tutt, A.N.J. et al., 2021 [PMID: 34062114](https://pubmed.ncbi.nlm.nih.gov/34062114/)) | In patients with gBRCA1/2 mutations and high-risk HER2- EBC, adjuvant olaparib for 1 year significantly improved invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) vs. placebo. | N/A (Initial Treatment) | Anemia, fatigue, nausea. Should be administered after completion of (neo)adjuvant chemotherapy. |\\n| **ER+/PR+, Node-Positive High-Risk EBC** | Adjuvant Abemaciclib + Endocrine Therapy | **monarchE Trial** (Johnston, S.R.D. et al., 2020 [PMID: 32954937](https://pubmed.ncbi.nlm.nih.gov/32954937/)) | In patients with node-positive, HR+, HER2- EBC, adding 2 years of abemaciclib to standard endocrine therapy significantly improved IDFS. | N/A (Initial Treatment) | Diarrhea (common), neutropenia, fatigue, risk of VTE. Requires monitoring of liver function and complete blood counts. |\\n| **ER+/PR+ & Premenopausal Status** | Ovarian Function Suppression (OFS) + Aromatase Inhibitor (AI) | **SOFT/TEXT Trials** (Francis, P.A. et al., 2015 [PMID: 25495490](https://pubmed.ncbi.nlm.nih.gov/25495490/)) | For premenopausal women, combining OFS with an AI (e.g., exemestane) resulted in significantly higher rates of disease-free survival compared to tamoxifen alone. | N/A (Initial Treatment) | Symptoms of menopause (hot flashes, vaginal dryness), bone density loss. |\\n| **Node-Positive Disease (N1)** | Adjuvant Chemotherapy | NCCN/ASCO Guidelines | Standard of care for node-positive breast cancer to reduce the risk of distant recurrence. A taxane- and anthracycline-based regimen is typical. | N/A (Initial Treatment) | Standard chemotherapy-related toxicities (myelosuppression, neuropathy, fatigue). |\\n\\n**Clinical Perspective:**\\nThe standard treatment pathway for this patient would begin with surgery (lumpectomy or mastectomy) and axillary lymph node dissection, followed by adjuvant chemotherapy (e.g., dose-dense AC-T). After chemotherapy, three powerful systemic therapies should be considered. Based on the OlympiA trial, one year of adjuvant olaparib is indicated. Concurrently or sequentially, endocrine therapy should be initiated. Given her high-risk, node-positive status and premenopausal age, the optimal endocrine strategy is Ovarian Function Suppression combined with an aromatase inhibitor. Furthermore, the monarchE trial data support the addition of two years of the CDK4/6 inhibitor abemaciclib to this endocrine backbone. The decision to use both olaparib and abemaciclib must be carefully weighed by a multidisciplinary team, considering cumulative toxicity and the patient's performance status, as there is limited data on their concurrent or sequential use outside of clinical trials. Adjuvant radiation therapy to the breast/chest wall and regional nodes is also a standard component of care.\\n\\n4. Multi-Target Opportunities\\n| Treatment Combination | Targeted Events | Evidence | Summary |\\n| :--- | :--- | :--- | :--- |\\n| **Adjuvant Chemotherapy -> Olaparib + OFS/AI + Abemaciclib** | Node-Positive Disease, Germline BRCA1 Mutation, ER+/PR+ Signaling | **OlympiA Trial**, **monarchE Trial**, **SOFT/TEXT Trials** | This multi-modal strategy targets the key vulnerabilities of the tumor. Chemotherapy addresses proliferation, olaparib exploits the HRR defect (synthetic lethality), and the endocrine/CDK4/6 inhibitor combination potently suppresses the ER-driven growth pathway. |\\n\\n**Analysis:**\\nThe most promising strategy for this patient involves the sequential and/or overlapping administration of therapies targeting distinct oncogenic pathways. The combination of a PARP inhibitor and potent endocrine blockade (OFS + AI + CDK4/6 inhibitor) after standard chemotherapy offers the greatest potential to reduce the high risk of recurrence in this patient population. While each agent is supported by Level 1 evidence from its respective pivotal trial, the optimal sequencing and safety of using all of them in concert is an area of active clinical investigation. Close monitoring for overlapping toxicities, particularly hematologic (from olaparib, abemaciclib, and prior chemotherapy) and gastrointestinal side effects, would be critical.\\n\\n### References\\n1.  Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., ... & Roch\u00e9, H. (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *New England Journal of Medicine*, *384*(25), 2394\u20132405. [PMID: 34062114](https://pubmed.ncbi.nlm.nih.gov/34062114/)\\n2.  Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., ... & Goetz, M. P. (2020). Abemaciclib in High-Risk, Early-Stage, HR+, HER2- Breast Cancer. *Journal of Clinical Oncology*, *38*(34), 3987\u20133998. [PMID: 32954937](https://pubmed.ncbi.nlm.nih.gov/32954937/)\\n3.  Francis, P. A., Regan, M. M., Fleming, G. F., L\u00e1ng, I., Ciruelos, E., Bellet, M., ... & Goldhirsch, A. (2015). Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. *New England Journal of Medicine*, *372*(5), 436\u2013446. [PMID: 25495490](https://pubmed.ncbi.nlm.nih.gov/25495490/)\\n\\n***\\n\\n**Disclaimer:** This report is for informational and research purposes only and does not constitute medical advice. The information provided is based on the patient data supplied and current medical literature. All treatment decisions must be made by a qualified clinician in consultation with a multidisciplinary tumor board, taking into account the full clinical context and the patient's individual circumstances and preferences.\"}],\"role\":\"model\"},\"grounding_metadata\":null,\"partial\":null,\"turn_complete\":null,\"error_code\":null,\"error_message\":null,\"interrupted\":null,\"custom_metadata\":null,\"usage_metadata\":{\"cache_tokens_details\":null,\"cached_content_token_count\":null,\"candidates_token_count\":2055,\"candidates_tokens_details\":null,\"prompt_token_count\":1319,\"prompt_tokens_details\":[{\"modality\":\"TEXT\",\"token_count\":1319}],\"thoughts_token_count\":1333,\"tool_use_prompt_token_count\":null,\"tool_use_prompt_tokens_details\":null,\"total_token_count\":4707,\"traffic_type\":null},\"live_session_resumption_update\":null,\"invocation_id\":\"e-05464017-10cc-4d26-8ec4-05e4cb204813\",\"author\":\"capricorn_medical_oncology_agent\",\"actions\":{\"skip_summarization\":null,\"state_delta\":{},\"artifact_delta\":{},\"transfer_to_agent\":null,\"escalate\":null,\"requested_auth_configs\":{}},\"long_running_tool_ids\":null,\"branch\":null,\"id\":\"6e61489a-37c7-4604-9b68-7870a5994023\",\"timestamp\":1754695837.370156}],\"last_update_time\":1754695837.370156},\"user_id\":\"user\"}],\"creation_timestamp\":1754695875.339651}"